NanoValent Pharmaceuticals has progressed so far thanks to various grants made available by the National Institute of Health (NIH), National Cancer Institute (NCI) and the National Science Foundation (NSF) for oncology, surgical, imaging and vaccine projects, founder investment and its first external seed investment during 2017.
NanoValent is now seeking additional external private investment to support pre-Investigational New Drug (IND) activities and, once an IND is achieved, will seek further funding to support the full clinical Proof of Concept (POC) phase.
Financial Conflict of Interest (FCOI) Policy
NanoValent Pharmaceuticals’ Financial Conflict of Interest (FCOI) policy document is available for download.